Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter
CINCINNATI, April 7, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary net revenues results for its second quarter of fiscal 2022. Preliminary unaudited net revenues for the second quarter of fiscal 2022 are expected to be between $109 million and $113 million, above Meridian’s expectations […]